ALSO NOTED: Sanofi files rimonabant NDA; MDS speeds transition; Solvay bids for Girindus; New Zomig data; and much more...

> Sanofi-Aventis has filed an NDA for rimonabant, which it believes can provide a comprehensive therapy for cardiovascular risks. Release

> Chutes & Ladders: Speeding its transition plans, Canada's MDS says that Stephen DeFalco will become CEO on July 1. Story

> Belgium's Solvay is making a friendly bid to acquire 51 percent of Girindus. Article

> AstraZeneca has presented new data for Zomig showing a 58.1 percent headache response rate among adolescents compared to 43.3 percent for patients taking a placebo. Release

> SciClone Pharmaceuticals of San Mateo, California, has submitted an IND for SCV-07, a synthetic dipeptide that has demonstrated activity against a broad range of viral and infectious diseases. Release

> RegeneRx Biopharmaceuticals of Bethesda, Maryland, has announced a $5 million equity investment. Release

> The European Medicines Agency has given orphan drug status to Nabi Biopharmaceuticals' Civacir for hepatitis C. Release

> Dynavax Technologies of Berkeley, California, has begun a Phase III trial of its hepatitis B vaccine. Release

And Finally... Once thought useless, researchers now say that chemotherapy can play a big role in prolonging the lives of lung cancer victims. Article

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.